Vivos Therapeutics, Inc.
VVOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $21,535 | $15,169 | $9,251 | $47,774 |
| - Cash | $6,260 | $1,643 | $3,519 | $24,030 |
| + Debt | $1,512 | $1,995 | $2,413 | $1,632 |
| Enterprise Value | $16,787 | $15,521 | $8,145 | $25,376 |
| Revenue | $15,031 | $13,801 | $16,024 | $16,885 |
| % Growth | 8.9% | -13.9% | -5.1% | – |
| Gross Profit | $9,019 | $8,271 | $10,019 | $12,604 |
| % Margin | 60% | 59.9% | 62.5% | 74.6% |
| EBITDA | -$10,555 | -$16,675 | -$24,362 | -$19,541 |
| % Margin | -70.2% | -120.8% | -152% | -115.7% |
| Net Income | -$11,136 | -$13,583 | -$23,845 | -$20,293 |
| % Margin | -74.1% | -98.4% | -148.8% | -120.2% |
| EPS Diluted | -2.22 | -11.14 | -25.9 | -23.89 |
| % Growth | 80.1% | 57% | -8.4% | – |
| Operating Cash Flow | -$12,691 | -$11,946 | -$19,587 | -$15,735 |
| Capital Expenditures | -$568 | -$803 | -$924 | -$2,396 |
| Free Cash Flow | -$13,259 | -$12,749 | -$20,511 | -$18,131 |